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Mutational status of TP53 together with expression of wild-type (wt) IGHV represents the 
most widely accepted biomarkers, establishing a very poor prognosis in B-cell chronic 
lymphocytic leukemia (B-CLL) patients. Adoptive cell therapy using allogeneic HLA-
mismatched Natural killer (NK) cells has emerged as an effective and safe alternative in 
the treatment of acute myeloid and lymphoid leukemias that do not respond to traditional 
therapies. We have described that allogeneic activated NK cells eliminate hematological 
cancer cell lines with multidrug resistance acquired by mutations in the apoptotic machin-
ery. This effect depends on the activation protocol, being B-lymphoblastoid cell lines 
(LCLs) the most effective stimulus to activate NK cells. Here, we have further analyzed 
the molecular determinants involved in allogeneic NK cell recognition and elimination of 
B-CLL cells, including the expression of ligands of the main NK cell-activating receptors 
(NKG2D and NCRs) and HLA mismatch. We present preliminary data suggesting that 
B-CLL susceptibility significantly correlates with HLA mismatch between NK cell donor 
and B-CLL patient. Moreover, we show that the sensitivity of B-CLL cells to NK cells 
depends on the prognosis based on TP53 and IGHV mutational status. Cells from 
patients with worse prognosis (mutated TP53 and wt IGHV) are the most susceptible 
to activated NK cells. Hence, B-CLL prognosis may predict the efficacy of allogenic 
activated NK cells, and, thus, NK cell transfer represents a good alternative to treat 
poor prognosis B-CLL patients who present a very short life expectancy due to lack of 
effective treatments.
Keywords: allogeneic nK cells, bad prognosis leukemia, mismatch, chronic lymphocytic leukemia, leukemia 
resistance
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inTrODUcTiOn
B-cell chronic lymphocytic leukemia (B-CLL), a heterogeneous 
disease with variable clinic presentation and evolution, is the 
most common leukemia in adults in Western World (1, 2). It is 
characterized by the accumulation of CD5+ B cells in peripheral 
blood and lymphoid organs (3). This leukemia is usually treated 
with chemotherapy and anti-CD20 antibodies (i.e., Rituximab) 
(4), but remains incurable largely due to development of refrac-
tory disease. This is frequently associated with the expression of 
molecular markers that confer bad prognosis (2).
Several prognostic and predictive markers have been described 
for B-CLL, including cytogenetic abnormalities like 17p and 
11q deletions, associated in some instances with rapid clinical 
progression, chemotherapy resistance, and inferior survival (5). 
Expression of membrane-proteins such as CD38 (6) and CD49d 
(7) or intracellular ZAP70 (8) have also been described as adverse 
prognostic factors. Among them, a recent study indicates that 
CD49d expression is the best immunophenotypic predictor 
of the overall patient survival (9). Some single mutations like 
NOTCH1 (10, 11), the splicing factor 3b (SF3B1) (12, 13), BIRC3 
(14), exportin 1 (XPO1), MYD88, and KLHL6 (15) have also been 
related to poor prognosis, although their utility as prognostic 
markers is still under clinical evaluation. Among all of them, 
TP53 mutation/deletion and expression of unmutated IGHV are 
widely accepted as indicators of poor prognosis at the time of 
diagnosis (16–19).
Unmutated IGHV is associated with higher aggressiveness of 
B-CLL cells since proliferating signals through B cell receptor are 
unaffected. In contrast, mutated IGHV produces unresponsive 
B cell receptors. TP53 is a tumor suppressor that plays a key role 
in DNA repair as well as apoptosis trigger in response to DNA 
damage. Thus, inactivation of TP53 favors malignant cell trans-
formation and confers resistance to chemo and radiotherapy (20).
Natural killer (NK) cells belong to the innate immune system 
and were originally identified as lymphocytes capable of killing 
cells that have downregulated MHC-I expression due to pathogen 
infection or transformation (21–26). They constitute a heteroge-
neous cell population with distinct phenotypic and functional 
characteristics, including, but not limited to, their ability to 
mediate cytolytic activity (27, 28). NK cell activity is regulated 
by the equilibrium between signals transduced by inhibitory and 
activating receptors, which dictates target cell elimination and 
pro-inflammatory cytokine production (29, 30). The main inhibi-
tory receptors, NKG2A killer-cell immunoglobulin-like recep-
tors (KIRs) family, bind to MHC-I molecules on target cells. The 
main activating receptors, NKG2D and NCRs (NKp30, NKp44, 
and NKp46) recognize stress ligands on target cells (31, 32). The 
balance between inhibitory and activating signals dictates if NK 
cells will recognize and destroy target cells.
During allogeneic hematopoietic stem cell transplantation, in a 
context of KIR–MHC mismatch, HLA alleles expressed on target 
cells may not inhibit NK cells. Accordingly, allogeneic NK cells 
have been proposed to kill hematological cancer cells and improve 
prognosis, mainly in the context of mismatched hematopoietic 
stem cell transplantation (33–37). Clinical protocols based on 
these concepts have been designed to treat some hematological 
malignancies, including lymphoma, acute myeloid and lymphoid 
leukemia, and multiple myeloma (34, 37–42). Regarding B-CLL, 
at present, it is unclear whether KIR–HLA mismatch may also 
regulate B-CLL allogeneic NK cell recognition. NK cells activated 
with high concentrations of IL-2, known as lymphokine-activated 
killer (LAK) cells, were shown to kill B-CLL cells (43–45). In 
contrast, other authors reported that autologous and allogeneic 
LAK cells were unable to kill B-CLL cells (46–48). More recently, 
it was shown that unstimulated NK cells did not kill B-CLL cells, 
but cytotoxicity was recovered using IL-15-activated NK cells in 
combination with rituximab (49). Clinical trials based on autolo-
gous NK cells have not shown benefits (50).
We have previously shown that the selection of a proper 
activating stimulus is critical to generate activated NK cells able 
to kill chemoresistant hematological cancer cell lines as well as 
cells from B-CLL patients (51, 52). Allogeneic NK cells activated 
in the presence of EBV-transformed B-cell lymphoblastoid cell 
lines (LCL) presented significantly higher cytotoxicity than those 
generated with K562 cells and IL-2/IL-15. This activation protocol 
has been now employed to (i) analyze the molecular determinants 
that drive allogeneic NK cell recognition of B-CLL cells and (ii) 
to test the susceptibility of adverse prognosis B-CLL cells, defined 
according to IGHV mutational status and TP53 deletion/muta-
tion, to allogeneic activated NK cells.
MaTerials anD MeThODs
isolation and activation of human nK 
cells
Human ex vivo NK cells were enriched by using anti-CD56 
MicroBeads with a MultiStand MACS (MACS, Miltenyi Biotec) 
from freshly isolated peripheral blood mononuclear cells 
(PBMCs).
Activation of human primary NK cells was pursued by cultur-
ing PBMCs for 5 days with Mitomycin C-treated R69- or 721.221-
LCL at 10:1 PBMC:stimulator ratio. Subsequently, NK cells were 
enriched using anti-CD56 MicroBeads with a MultiStand MACS 
(MACS, Miltenyi Biotec).
PBMCs were obtained from blood from healthy donors by 
Ficoll gradient centrifugation (Blood and Tissue Bank of Aragon; 
approved by the CEICA, number: C.I.PI11/006). NK cell purity 
(CD56+/CD3−) was higher than 90% in all cases. Contamination 
with CD8+ CD3+ cells was less than 2%.
B-cll Patients
Blood samples from patients with B-CLL were obtained from 
Hospital Clinico Lozano Blesa (Zaragoza) and Hospital Puerta 
de Hierro-Majadahonda (Madrid). They were processed by Ficoll 
gradient centrifugation to obtain PBMCs and stored frozen in 
liquid nitrogen until their use. In all cases, the percentage of 
CD19+CD5+ cells was higher than 80% and no differences were 
observed between frozen and fresh B-CLL cells regarding their 
susceptibility to NK cells. This study was approved by Ethics 
Committee for Clinical Research of Aragon (CEICA), number: 
C.I.PI11/006; and by Ethics Committee for Clinical Research of 
Hospital Puerta de Hierro-Majadahonda, number: PI31_13.
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analyses of TP53 and IGHV Mutational 
status
IGHV gene mutational status was analyzed and classified accord-
ing to ERIC recommendations (53). TP53 genetic abnormalities 
were detected by conventional cytogenetics, FISH, and Sanger 
sequencing analysis.
nK cell-Mediated cytotoxicity
NK cells were labeled with 1 μM of CellTracker™ Green CMFDA 
(Life Technologies) and incubated with target cells at 9:1 e:t ratio 
for 4 h. Subsequently, phosphatidylserine (PS) translocation and 
membrane damage were analyzed in the green or violet fluores-
cence negative target cell population by flow cytometry using 
annexin V and 7AAD as previously described (51).
analyses of hla genotype and Prediction 
of Kir–hla Mismatch
Killer-cell immunoglobulin-like receptor ligands were deduced 
from the cell HLA types, determined by standard methods 
approved by the European Federation for Immunogenetics, as in 
Ref. (54) or directly assessed by PCR with sequence-specific prim-
ers targeted to the critical polymorphic positions (oligonucleotide 
sequences and PCR conditions available upon request). Mismatch 
was defined, according to the missing-self model, as the absence 
in the target cell of a KIR ligand present in the effector cells.
Flow cytometry
The antibodies against HLA-E-PE (clone 3D12), HLA-ABC/E/
F/G-FITC (clone W6/32), DR4-PE (clone DJR1), and DR5-PE 
(clone MD5-1) were from eBioscience. The antibody against 
ICAM-1-APC (clone HA58) was from BD. The antiCD19-APC 
(clone LT19) and antiCD5-FITC (clone UCHT2) were from 
Miltenyi Biotec. The NKR-Fc quimeras were from R&D Systems 
(NKG2D-Fc) or were provided by Miguel López-Botet (NKp30-Fc 
and NKp46-Fc). The anti-human IgG secondary antibody labeled 
with PE was from Jackson Immunoresearch. All antibodies were 
diluted in PBS with 5% FCS and 0.1% sodium azide for cell stain-
ing. To stain NKR ligands using NKR-Fc quimeras, cells were 
blocked with rabbit serum before staining with the respective 
chimeras.
statistical analyses
Statistical analyses were performed using the GraphPad Prism 
v 4.0 software by one-way analysis of variance (ANOVA) as 
indicated in the figure/table legends. Regression-tree analyses 
(Decision tree learning) were used to classify B-CLL samples 
according to its susceptibility to NK cells. This is a predictive 
model that maps the values of cell death (percentage) to conclu-
sions about categorical predictor variables.
resUlTs
nK cells require activation to  
Kill cll cells
As mentioned above, it is unclear whether NK cells activated 
with exogenous cytokines may kill B-CLL cells. Our group 
has previously described that NK cells activated with EBV-
transformed R69 or 721.211 LCLs are able to eliminate cells 
from B-CLL patients without requiring supplementation with 
exogenous cytokines (51). Importantly, activated NK cells did not 
kill healthy non-transformed PBMCs. Here, we confirmed that 
the cytotoxic potential of NK cells activated with R69 LCLs was 
increased in comparison with freshly isolated NK cells from the 
same donors. As shown in Figure 1A, freshly isolated allogeneic 
NK cells from healthy donors did not kill B-CLL cells. In contrast, 
activated NK cells presented a significantly increased cytotoxic 
potential against B-CLL cells, even in cells from a patient (CLL2) 
with chemotherapy and Rituximab resistance (Table 1). Killing of 
Jurkat cells and R69 LCL (that expresses all known HLA ligands 
for inhibitory KIRs) was also significantly enhanced after NK cell 
activation. Cell death was almost completely inhibited by EGTA 
indicating the granule exocytosis was the main mechanism 
employed by NK cells to kill B-CLL cells (data not shown). As 
previously found in NK cells activated with R69 LCLs (51), the 
NK cell receptors NKG2A, NKp30, NKp44, and DNAM and the 
cytotoxic protease granzyme B were upregulated in activated NK 
cells (data not shown).
Next, we analyzed whether HLA-I expression in the LCLs 
used to activate NK cells might influence their anti-leukemic 
potential. To this aim we compared the cytotoxic activity of NK 
cells from 4 independent donors, activated either with HLA-I+ 
R69 LCLs or with HLA-I− 721.221 cells, against B-CLL cells from 
four different patients. As shown in Figure  1, although with 
some individual variations, the cytotoxic potential of activated 
NK cell did not depend on HLA-I expression in stimulating 
LCLs (Figure  1B). Thus, we employed NK cells isolated from 
PBMC cultures activated for 5 days with R69 LCLs in the next 
experiments.
expression of nK cell ligands  
by B-cll cells
Our data confirm that LCL-activated NK cells are able to kill 
B-CLL cells. However, we have previously found that the cyto-
toxic potential of allogeneic NK cells against B-CLL cells varies 
depending on the NK cell donor/B-CLL patient pair (51).
Thus, experiments were set up to address the basis for the vari-
able susceptibility of B-CLL cells to activated NK cells. Seven NK 
cell donors and six B-CLL patients were selected, and the level of 
cell death was evaluated in all combinations (42). Four and three 
different NK cells donors were blindly incubated with the six 
B-CLL patients on two different days. As shown in Figure 2A, the 
level of cell death varied depending on the pair of NK cell donors 
and B-CLL patients incubated in agreement with our previous 
results (51). Some donors like the one represented with circles 
presented a similar profile of killing against all CLL samples. 
However, this was not a general trend since others like the ones 
represented with triangles, diamonds, or inverted triangles pre-
sented a high variability depending on the CLL sample. Indeed, 
the profile of killing between the different NK cell donors was 
statistically similar (Supplementary figure). These killing profiles 
were not dependent on the level of NK cell activation since all 
of them similarly killed Jurkat cells and expressed comparable 
TaBle 1 | characteristics of cll patients used in the study of 
compatibility.
sample stage  
(diagnosis/sample)
Previous treatment response
CLL1 0/III R-FC Complete 
remission
CLL2 0/IV F; C; COP; R-FC No response
CLL3 IV/0 R-FC Complete 
remission
CLL4 I/III Chlorambucil Partial remission
CLL5 0/0 Chlorambucil Partial remission
CLL6 0/0 None
CLL7 0/IV R-COP; R-chlorambucil; 
R-BENDA/Idelalisib
No response
CLL8 IV/IV Chlorambucil No response
CLL9 0/0 Splenectomy Partial remission
R, rituximab; F, fludarabine; C, cyclophosphamide; O, vincristine; P, prednisone; 
BENDA, bendamustine.
FigUre 1 | allogeneic nK cells require activation to kill B-cll cells. (a) Jurkat and R69 cells or cells from B-CLL patients were incubated with naïve (left) or 
R69-LCL activated (right) NK cells (MACS enriched, >90% CD56+CD3− cells; CTGreen labeled) for 4 h at 9:1 effector:target ratio as described in Section “Materials 
and Methods.” Subsequently, PS traslocation (annexin V DY634) and membrane permeabilization (7AAD uptake) were analyzed by flow cytometry in the cell 
population negative for CTGreen. (B) Cells from B-CLL were incubated with R69- or 721-LCL-activated NK cells (MACS enriched, >90% CD56+CD3− cells; 
CTGreen labeled) for 4 h at 9:1 effector:target ratio as described in Section “Materials and Methods.” Subsequently, PS traslocation (annexin V DY634) and 
membrane permeabilization (7AAD uptake) were analyzed by flow cytometry in the cell population negative for CTGreen. Data in the graphics are represented as the 
mean ± SEM from three independent NK cell donors (a) or from 14 independent B-CLL patients (B). Annexin V+ cells represent the % of AnnexinV+7AAD− plus 
AnnexinV+7AAD+ cells. Statistical analysis was performed by comparing the means of naive versus activated NK cells within each group using 2-way ANOVA with 
Tukey HSD post hoc test; ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001. (c) Representative dot plot of Annexin V/7AAD staining in a B-CLL sample 
incubated in medium alone (control) or together with NK cells (NK). Numbers correspond to the % of cells in each quadrant.
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levels of granzyme B, NKG2D, and NCRs (NKp30, Nkp44, and 
Nkp46) (data not shown). Thus, a priori, this variability could 
be partly explained by (i) the degree of HLA–KIR mismatch 
between donor and patient as found in AML and ALL or (ii) the 
intrinsic resistance of cells from some B-CLL patients to activated 
NK cells.
As shown in the regression-tree analysis in Figure 2B, some 
B-CLL cells like CLL1 and CLL6 are more resistant than oth-
ers to activated NK cells, irrespectively of the NK cell donor, 
supporting our second hypothesis. Thus, we decided to analyze 
the reason for the increased resistance of CLL1 and CLL6 to 
activated NK cells. First, we analyzed whether this could be 
related to the level of expression of ligands recognized by the 
NK cell receptors NKG2D, NKp30, NKp46, KIRs, and LFA-1. 
As shown in Figure 3A, the expression of NKG2D and NKp30 
ligands were very low in most CLL samples, and only some CLLs 
expressed higher levels of NKp46 ligands. Jurkat cells expressed 
ligands for all these receptors, validating our approach. Next, we 
analyzed the expression of the adhesion molecule ICAM-1 and 
of HLA-I using both an antibody (clone W6/32) that recognizes 
all HLA-I molecules and another one specific for HLA-E. As 
shown in Figure 3B, all cells expressed HLA-I (ABC/E/F/G and 
E) and ICAM1, although the level of expression was quite vari-
able. Of note, the level of expression of HLA-ABC and HLA-E 
in CLL1 and CLL6 was higher in comparison with the other 
B-CLL samples, suggesting that this expression could be related 
FigUre 2 | analyses of the cytotoxic potential of activated allogeneic nK cells employing six cll patients and seven nK cell donors. Cells from 
B-CLL patients were incubated with R69-activated NK cells (MACS enriched, >90% CD56+CD3− cells; CTGreen labeled) from seven independent donors for 4 h at 
9:1 effector:target ratio in two independent experiments as described in Section “Materials and Methods.” Subsequently, PS traslocation (annexin V DY634) and 
membrane permeabilization (7AAD uptake) were analyzed by flow cytometry in the cell population negative for CTGreen. (a) The graph represents the % of annexin 
V positive cells in the 42 combinations (six B-CLL × seven NK). Annexin V+ cells represent the % of Annexin V+7AAD− plus AnnexinV+7AAD+ cells. Each symbol 
represents a NK cell donor. All NK cell donors were incubated with every B-CLL sample. (B) Cell death (Annexin V+) in every B-CLL sample was represented in a 
boxplot where median ± SD is indicated. Statistical analysis was performed employing a regression tree in which patient samples are clustered according to their 
similarity of sensitivity to NK cell cytotoxicity.
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to the increased resistance of these samples. However, blocking 
of CD94 in NK cells, a protein required for the inhibitory sign-
aling of the HLA-E ligand NKG2A, by using specific antibodies 
did not significantly enhance NK cell-mediated cytotoxicity 
(data not shown) suggesting that HLA-E expression in CLL1 
and CLL6 was not the main responsible for NK cell resistance.
The adhesion molecule ICAM-1 was expressed by all B-CLL 
samples (Figure 3C), and the level of expression did not correlate 
with NK cell susceptibility. Although we did not test other adhe-
sion molecules involved in NK cell recognition like LFA-3, we 
have previously shown that blocking ICAM-1/LFA-1 interaction 
almost completely eliminate NK cell cytotoxicity in hematologi-
cal cancer cells (including B-CLL) [(55) and data not shown] sug-
gesting a minor role for other adhesion molecules.
Kir–hla receptor–ligand Mismatch
As mentioned above KIR–HLA mismatch has been shown to 
promote NK cell-mediated elimination of some hematological 
neoplasias, including acute monocytic and lymphocytic leuke-
mias, and to a lesser extent multiple myeloma (56). However, 
this effect is not clear for B-CLL, and it could help to explain the 
different susceptibility of some B-CLL cells. Thus, we analyzed 
whether mismatches between NK cell donor KIRs and patient 
HLA ligands (HLA-A3/A11, -Bw4, -C1/2) would explain the 
differences observed. To this end, we determined the HLA 
epitopes for the seven NK cell donors and the six B-CLL patients. 
The results of these analyses are shown in Table  2 where the 
expression of known ligands for KIR3DL2 (A3/A11), KIR3DL1 
(Bw4), KIR2DL1 (C2), and KIR2DL2/2DL3 (C1) are indicated.
Based on the degree of KIR ligand compatibility in donor 
to patient direction, we predicted matched (compatible) and 
mismatched (incompatible) combinations in the 42 NK-CLL 
pairs and analyzed whether the degree of mismatch significantly 
correlated with the susceptibility observed in the B-CLL samples. 
A summary of the percentage of matched (0) and mismatched 
(1) combinations is shown in Table  3. As expected, since the 
experimental design followed a double blind protocol, in which 
HLA genotype and mismatch was analyzed after testing NK 
cell-mediated cytotoxicity, a higher number of unmatched than 
matched combinations were analyzed. However, as shown in 
Figure 3, matched and unmatched NK-CLL combinations were 
tested at the same time, which partially compensate this potential 
limitation. As shown in Figure 4, except for one NK cell donor 
in CLL1, matched NK cell donors induced the lowest level of cell 
death in every B-CLL case, although in some instances differ-
ences were low. The median cell death in compatible B-CLL/NK 
cell combinations was 18%, and this value increased to 34% in 
mismatched combinations (Table 4). These differences became 
FigUre 3 | analyses of the expression of activating and inhibitory 
ligands of nK cell receptors in B-cll cells. Expression of NKp30, 
NKp46, and NKG2D activating ligands using Fc quimeras (a), HLA-ABC and 
HLA-E inhibitory ligands (B), and the adhesion molecule ICAM-1 (c) using 
specific antibodies were analyzed in B-CLL cells by flow cytometry as 
described in Section “Materials and Methods.” The Mean fluorescence 
intensity (MFI) of every B-CLL sample is represented in the graphs. 
MFI = (MFI specific Ab) − (MFI isotype control).
TaBle 2 | Kir ligands expressed in cll patients and nK cell donors 
used in the study of compatibility.
Dna lig 3Dl2 lig 3Dl1 lig 2Dl1 lig 2Dl2 2Dl3
CLL1 − + + +
CLL2 − − + +
CLL3 − + + −
CLL4 − + − +
CLL5 − − + +
CLL6 + + − +
CLL7 − + + +
NK1 − + + −
NK2 − + + +
NK3 + + − +
NK4 − + + +
NK5 − + − +
NK6 − + + −
NK7 − + + +
TaBle 3 | Distribution of matched (0)/mismatched (1) combinations for 
each cll patient.
cll compatibility
0 (%) 1 (%)
1 6 (86) 1 (14)
2 0 (0) 7 (100)
3 2 (29) 5 (71)
4 1 (14) 6 (86)
5 0 (0) 7 (100)
6 2 (29) 5 (71)
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statistically significant using a one mixed-model analysis of 
variance (ANOVA). The model controlled for the within-subject 
nature of the seven NK cell donors by including random effects 
for B-CLL patient and B-CLL patient × NK cell interaction. Thus, 
although the statistical significance was close to 0.05, it should 
be noted that the model used for these analyses is very conserva-
tive taking into account that there is a non-controlled intrinsic 
variability in the components within each group (NK cell donors 
and B-CLL patients). Thus there was a good correlation between 
mismatching and NK cell cytotoxicity supporting that NK cell 
alloreactivity explains the variability observed in each B-CLL 
sample.
Poor Prognosis B-cll cells are More 
susceptible to activated nK cells than 
good Prognosis B-cll cells
Although mismatch partly explained the variability observed in 
the different B-CLL/NK cell combinations, our results also sug-
gest that in each B-CLL case there is/are intrinsic characteristic/s 
that regulate/s the susceptibility of B-CLL cells to NK cells which 
is independent on the expression of NK cell receptor ligands.
When we analyzed retrospectively the clinical evolution 
(response to treatment) of these patients, we realized that except 
for CLL3, paradoxically, samples from patients with a better 
response (CLL1) or in which no treatment was required (CLL6) 
were those more resistant to NK cell cytotoxicity (Table  1; 
Figure  2B). In contrast, the patient that did not respond to 
treatments (CLL2) was the most susceptible to NK cells. Based 
on this observation, we established a new experiment to analyze 
in more detail whether the prognosis of CLL patients correlated 
with the susceptibility of B-CLL cells to NK cells. Prognosis was 
established by determination of TP53 and IGHV mutational 
status as previously shown (16–19). Three different groups of 
B-CLL patients were established retrospectively according to the 
expression of wild-type (wt) or mutated/deleted (mut) TP53 and 
wt or mut IGHV: TP53wtIGHV mut (nine patients), TP53wtIGHVwt 
(eight patients), and TP53mutIGHV wt (five patients) as good, 
intermediate, and poor prognostic groups (Table 5). The sam-
ples of these groups were blindly incubated with NK cells from 
several donors randomly selected and the level of cell death was 
determined.
As shown in Figure  5, the susceptibility of B-CLL cells to 
NK cells was clearly enhanced in the worse prognostic group in 
comparison with good and intermediate prognosis. Expression 
of wt IGHV in the context of wt TP53 also increased the suscep-
tibility of B-CLL cells to NK cells although did not reach statistic 
significance.
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DiscUssiOn
Allogeneic NK cells have been shown to be effective in the treat-
ment of poor prognosis acute myeloid and lymphoid leukemia 
(AML and ALL) (34, 37–42). Here, we show that allogeneic 
activated NK cells also recognize B-CLL cells and that, as shown 
for AML and ALL, our results suggest that recognition might be 
partially dependent on HLA mismatch. In addition, we show that 
allogeneic NK cells are able to efficiently kill leukemic cells from 
B-CLL patients with very poor prognosis categorized according 
to expression of mutated TP53 and wt IGHV. Notably, a worse 
prognosis was associated with an increased susceptibility of 
B-CLL cells to activated NK cells suggesting that those tumors 
expressing more aggressive phenotypes due to mutations may be 
good targets for NK cell immunotherapy. Indeed, it has recently 
been shown that B-CLL cells expressing wt IGHV present a 
higher number and a different pattern of somatic mutations, 
conferring those associated with IGHV a more aggressive and 
drug-resistant phenotype (15, 57, 58). Although we do not have 
yet a molecular explanation for this finding, it suggests that 
activated allogeneic NK cells could be a good alternative to treat 
them. Indeed, these results are somehow in agreement with 
FigUre 4 | correlation between matched B-cll/nK cell combinations and cell death. The data in Figure 2 were now represented as matched and 
mismatched combinations. The graph represents the % of annexin V+ cells in the 42 combinations (six B-CLL × seven NK) as described in legend to Figure 2 
separated in two independent experiments (NK1-4 and NK5-7). White and solid symbols correspond to mismatched and matched combinations, respectively. 
Statistical analyses and results are described in Tables 4 and 5.
previous findings indicating that cells with a higher resistance 
like undifferentiated/stem like tumors are more susceptible to 
NK cells (59–63). Since two different cohorts of patients were 
used for these studies, the formal proof that a combination of 
mismatch and prognosis predicts the sensitivity of B-CLL cells 
to allogeneic NK cells is still lacking. However, our data suggest 
that both factors should be taken into account when selecting 
therapies against bad prognosis B-CLL.
Controversial findings have been reported on the susceptibil-
ity of B-CLL cells to NK cells. Some studies found that activation 
of NK cells with IL2 increased its cytotoxic potential against 
B-CLL cells (43–45), by contrast others reported opposite results 
(46–48). However, these studies did not analyze the degree of 
HLA compatibility between donor NK cells and B-CLL cells, 
which could explain these a priori contradictory results. A general 
explanation for the relative resistance of B-CLL cells to syngeneic 
NK cells is the low expression of NKR ligands in B-CLL cells 
together with a high expression of classical HLA-I genes (64–66). 
Although we have not specifically identified which NKRs are 
involved in the elimination of B-CLL cells, our data suggest that 
allogeneic activated NK cells recognize and kill B-CLL cells even 
expressing low levels of activating NKR ligands. An enhanced 
NKR expression after activation as previously found (51) and 
a reduction of inhibitory signals due to HLA mismatch would 
promote the allogeneic NK cell response against B-CLL cells. 
This strategy is being currently used to develop therapeutic 
alternatives like blocking KIR with the antibody, Lirilumab (67). 
In this case the effect maybe more limited due the inability of 
patient NK cells to be reactivated against leukemic cells. Our 
results suggest that combining activated NK cells with blocking 
KIR antibodies might enhance the therapeutic potential of these 
therapies.
Another critical factor that may explain the differences 
regarding the susceptibility of B-CLL cells to NK cells is the 
use of NK cells activated under different protocols. We have 
previously found the stimulus employed to activate NK cells 
is critical in predicting the effectiveness of NK cells against 
resistant hematological cancer cells (51, 52). Thus, in contrast 
TaBle 4 | statistical analyses of the difference in cell death between 
matched (0) and mismatched (1) groups.
compatibility
0 (%) 1 (%)
Min 3.4 11.2
1st qu 11.8 24.83
Median 16 37
Mean 18.49 34
3rd qu 24.65 34
Max 34.80 54.75
numDF denDF F-value p-value
Intercept 1 35 74 0
Incompatible 1 35 4.262 0.046
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to studies mainly employing cytokines (IL-2 and/or IL-15) 
to activate NK cells, we have used here an EBV-transformed 
B-LCL as feeder cells. This protocol has been shown to enhance 
NK-mediated cytotoxicity against hematological neoplasia 
more efficiently than cytokines even in combination with K562 
feeder cells (51, 52).
Following this protocol, we have analyzed the molecular 
determinants that might explain the relative resistance of 
B-CLL to NK cells. First, we have confirmed that activation is 
a prerequisite to generate allogeneic NK cells able to kill B-CLL 
cells. We ruled out that the activation level of NK cells from the 
different donors was responsible for the different susceptibility 
of B-CLL [Data not shown and (51)]. In addition, we did not find 
a clear correlation between expression of ligands for the major 
activating NK cell receptors (e.g., NKG2D, NKp30, and NKp46) 
or the ICAM-1 adhesion molecule and B-CLL susceptibility 
to NK cells. Concerning the major ligands for NK inhibitory 
receptors, a good correlation between HLA-ABC and HLA-E 
expression and B-CLL susceptibility to NK cells was observed. 
However, a more rigorous analysis of HLA-ABC expression 
should be performed in a higher number of samples to reach a 
clear conclusion.
Employing a total of 42 NK donor-B-CLL patient combina-
tions, we obtained data suggesting that HLA mismatching was 
associated with the level of susceptibility of every B-CLL case. 
However to definitively confirm it, the expression of KIRs at 
the protein level should be also analyzed in a higher number of 
combinations, as a receptor–ligand model could improve the 
prediction of NK cell effectivity (68). Despite these potential 
limitations, our results underline the importance of selecting 
a suitable NK cell donor to treat a given B-CLL patient. In 
particular the analysis of HLA mismatch would be useful to 
readily exclude NK cell donors with low effectivity (compatible). 
Yet, testing susceptibility to NK cells from mismatched donors 
in vitro is mandatory to select a good NK cell donor, since B-CLL 
from some patients are inherently more resistant than others, 
irrespectively of HLA mismatch.
The general resistance of some B-CLL patients could be due to 
previously reported immune evasion mechanisms, i.e., shedding 
of NK cell receptor-soluble ligands (66). Although these authors 
did not test the role of HLA mismatch in B-CLL resistance, and 
we have not formally tested this potential evasion mechanism, 
our data comparing the susceptibility of B-CLL cells from patients 
with good, intermediate, and bad prognosis suggest that the low 
susceptibility of some B-CLL patients is paradoxically related 
with a less aggressive cancer cell phenotype.
Irrespective of which signals regulate NK cell recognition 
of B-CLL cells, it seems clear that expression of poor prognosis 
markers like mutated or deleted TP53 and wt IGHV, related 
to low life expectancy, may be converted into a chance to 
employ activated allogeneic NK cells to treat aggressive B-CLL 
phenotypes. Studies employing larger cohort or patients and 
clinical trials will be required to confirm the therapeutic value 
of our findings. Encouraging the development of these trials 
our conclusions are supported by recent findings indicating that 
allogeneic stem cell transplantation is a good option for poor 
prognosis B-CLL if the balance between GVL effect and GVHD 
is evaluated properly (69).
TaBle 5 | characteristics of cll patients used in the study of susceptibility in relation to prognosis.
sample stage (diagnosis/sample) Previous treatment response FishcYTa ighV status TP53/ighV status
LC15001 I/I N 13q IGHV4-34 P53wt/IGHVm
LC15004 I/I N 13q IGHV3-74 P53wt/IGHVm
LC15006 I/I N N IGHV1-2 P53wt/IGHVm
LC15007 0/0 N N IGHV4-39 P53wt/IGHVm
LC15012 I/I N N IGHV3-49 P53wt/IGHVm
LC15014 I/IV BENDA Partial remission (dead) 13q IGHV4-34 P53wt/IGHVm
LC15015 0/0 N N IGHV3-30 P53wt/IGHVm
LC15030 I/II Chl Partial remission (dead) 11q IGHV3-74 P53wt/IGHVm
12909A I/I N N  P53wt/IGHVm
LC15003 I/II N 12 IGHV4-39 P53wt/IGVHwt
LC15008 II/II R-Chl Partial remission (dead) 13q IGHV4-39 P53wt/IGHVwt
LC15009 0/0 N N IGHV3-20 P53wt/IGHVwt
LC15010 II/II Chl No response 12 IGHV1-18 P53wt/IGHVwt
LC15011 I/I R-FC LITE No response (dead) 12 IGHV4-39 P53wt/IGHVwt
LC15013 II/II R-FC Complete remission 11q IGHV4-b P53wt/IGHVwt
LC15032 II/II R-FC Partial remission N IGHV3-21 P53wt/IGHVwt
LC15061 0/0 GA101- Chl Partial remission nodular 13q IGHV1-2 P53wt/IGHVwt
LC15033 0/I R-BENDA Complete remission p53 IGHV1-69 P53m/IGHVwt
LC15055 II/II BENDA Partial remission p53 IGHV1-69 P53m/IGHVwt
16238A 0/IV R-FCM + Rm Complete remission p53 IGHV3-9 P53m/IGHVwt
17114A II/III R-FC No response (dead) p53 IGHV4-39 P53m/IGHVwt
15267A 0/IV R-FC No response (dead) p53 IGHV3-7 P53m/IGHVwt
R, rituximab; F, fludarabine; C, cyclophosphamide; BENDA, bendamustine; Chl, chlorambucil; M, mitoxantrone; GA101, Obinutuzumab; LITE, increased R dose and reduced FC 
dose; N, none.
aGenetic abnormalities found by FISH: trisomy 12, 11q and 13q deletion: p53 deletion/mutation.
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FigUre 5 | Poor prognosis B-cll cells are more susceptible to 
allogeneic r69-lcl-activated nK cells than good prognosis samples. 
R69-LCL-activated allogeneic NK cells (MACS enriched, >90% CD56+CD3− 
cells; CTGreen labeled) were incubated for 4 h at 9:1 effector:target ratio with 
B-CLL cells from three groups of patients classified according to prognosis 
based on the mutational status of TP53 and IGHV (good: TP53 wtIGHV mut, 
n = 9; intermediate: TP53 wtIGHV wt, n = 8; bad: TP53 mutIGHV wt, n = 5). 
Subsequently, PS traslocation (annexin V DY634) and membrane 
permeabilization (7-AAD uptake) were analyzed by flow cytometry in the cell 
population negative for CTGreen. Annexin V+ cells represent the % of 
AnnexinV+7AAD− plus AnnexinV+7AAD+ cells. Every B-CLL sample was 
incubated with NK cells from the several healthy donors and the % of 
Annexin V+ cells for every B-CLL sample were represented in a boxplot 
where median ± SD is indicated. Statistical analysis was performed by 
comparing the means of every group using 1-way ANOVA with Tukey HSD 
post hoc test; ns, not significant, *p < 0.05, ***p < 0.001.
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